Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Rezetecan + mFOLFOX6 + Bevacizumab in 1L HER2+ Advanced Colorectal Cancer
NCT07796763Phase 2Not yet recruiting
- Sponsor
- Hengrui
- Start
- Nov 2026
- Primary completion
- May 2028
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan in colorectal cancer (CRC), sponsored by Hengrui. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07796763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07796763.